Physician profile
Jesse Wayne Johnson
NPI 1245344571
$2,024.44
in general payments reported to CMS, 2019-2025
26 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $118 · 2021: $42.65 · 2022: $169 · 2023: $586 · 2024: $283 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $259.68 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $218.12 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $211.09 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $146.58 | 2019-2024 | |
| Glaxosmithkline, LLC. | $114.35 | 2019-2025 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $114.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.82 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals Lp | $95.28 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $92.86 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $88.49 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $83.70 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $61.54 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $50.71 | 2020-2022 | |
| Amarin Pharma, INC. | $49.11 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.68 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $40.91 | 2019 | |
| Corcept Therapeutics | $38.27 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.26 | 2023-2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $32.60 | 2022-2023 | Quviviq |
| Pfizer INC. | $31.84 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $23.23 | 2019 | |
| Esperion Therapeutics, INC. | $19.64 | 2025 | Nexletol |
| Genentech USA, INC. | $17.80 | 2019 | |
| Biogen, INC. | $17.60 | 2022 | |
| Phadia US INC. | $14.76 | 2023 | Immunocap |
| Merck Sharp & Dohme LLC | $12.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.